73 related articles for article (PubMed ID: 3501452)
1. [Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy].
Kikuchi Y; Kizawa I; Oomori K; Iwano I; Kita T; Miyauchi M; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Nov; 39(11):1987-92. PubMed ID: 3501452
[TBL] [Abstract][Full Text] [Related]
2. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy.
Kikuchi Y; Kizawa I; Oomori K; Iwano I; Kita T; Kato K
Jpn J Cancer Res; 1988 Jan; 79(1):125-30. PubMed ID: 3128500
[TBL] [Abstract][Full Text] [Related]
3. Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma.
Kikuchi Y; Kizawa I; Oomori K; Iwano I; Kita T; Miyauchi M; Kato K
Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1185-90. PubMed ID: 3138120
[TBL] [Abstract][Full Text] [Related]
4. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
[TBL] [Abstract][Full Text] [Related]
5. [The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs].
Fujisawa S; Suzumori K; Yasui Y; Yamamoto T; Yagami Y
Gan No Rinsho; 1986 Jan; 32(1):65-70. PubMed ID: 3485203
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 activity and the response of peripheral blood lymphocytes in patients with gynecologic malignancies.
Iwano I; Kikuchi Y; Oomori K; Kizawa I; Kita T; Kato K
Cancer Detect Prev; 1988; 12(1-6):583-8. PubMed ID: 3263201
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice].
Ishii K; Kita T; Hirata J; Tode T; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Apr; 45(4):333-9. PubMed ID: 8509669
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects].
Facchini V; Gadducci A; Ceccarelli P; Dell'Arciprete T; Del Bravo B; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1986; 107(6):359-68. PubMed ID: 3566043
[No Abstract] [Full Text] [Related]
11. The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
Kohorn EI; Klein-Angerer S
Gynecol Oncol; 1984 Sep; 19(1):60-6. PubMed ID: 6432636
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
13. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
Krommer CF; Szalai JP
Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
[TBL] [Abstract][Full Text] [Related]
14. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin-based chemotherapy regimens.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1869-71. PubMed ID: 2697190
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J; Bennett TZ; Hilgers RD
Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
[TBL] [Abstract][Full Text] [Related]
17. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
[TBL] [Abstract][Full Text] [Related]
18. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
[TBL] [Abstract][Full Text] [Related]
19. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
Sevelda P
Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
[TBL] [Abstract][Full Text] [Related]
20. Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma.
Conte PF
Bull Cancer; 1993 Feb; 80(2):152-5. PubMed ID: 8173167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
